Press releases
Access archived Guidant press releases
Access archived BTG press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 14, 2014First implant took place in France, at the Nouvelles Cliniques Nantaises in Nantes
Boston Scientific Corporation (NYSE: BSX) announces CE Mark approval and European market launch of the INGEVITY™ family of magnetic resonance...
Mar 12, 2014Newest Bare Metal Stent Technology Features Advanced Architecture and Provides Physicians with Enhanced Treatment Option for PatientsContinuing to advance leading stent technology, Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the REBEL™ Platinum...
-
Mar 3, 2014
The Board of Directors of Boston Scientific Corporation (NYSE: BSX) has elected Edward J. Ludwig as a Director. The appointment of Mr. Ludwig will...
-
Feb 28, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Barclays Global Healthcare Conference on March 11 in Miami Beach. Dan...
-
Feb 26, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Cowen and Company 34th Annual Healthcare Conference on March 4 in Boston....
-
Feb 24, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in two conferences, the 2014 Citi Global Healthcare Conference and the RBC...
-
Feb 14, 2014Fully Covered Metal Stent Provides New Treatment Option for Patients with Refractory Benign Esophageal Strictures
Boston Scientific Corporation (NYSE: BSX) has received CE Mark in Europe for its WallFlex™ Esophageal Fully Covered Stent to treat refractory benign...
Feb 5, 2014System Provides Physicians New Option for Treating Complete Blockages in the Major Arteries of the LegBoston Scientific (NYSE: BSX) has announced the U.S. launch and first use of the OffRoad™ Re-Entry Catheter System, an important addition to the...
-
Feb 4, 2014Fourth Quarter Marks Third Consecutive Quarter of Improved Performance
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.838 billion during the fourth quarter ended December 31, 2013. This represents 5...
-
Feb 3, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2014 Leerink Swann Global Healthcare Conference on Wednesday, February...
-
Jan 21, 2014
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the fourth quarter and full year ended...
-
Jan 6, 2014Boston Scientific Names Craig Thompson, M.D. As New Chief Medical Officer, Interventional Cardiology
Boston Scientific Corporation (NYSE: BSX) announces the appointment of Craig Thompson, M.D., as senior vice president and chief medical officer,...
-
Jan 2, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 32nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2014 in
-
Dec 17, 2013
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval of its X4 line of quadripolar CRT-D systems, including the AUTOGEN™ X4,...
-
Dec 16, 2013
The Board of Directors of Boston Scientific Corporation (NYSE: BSX) has elected David Roux as a Director. The appointment of Mr. Roux will fill a...
-
Dec 11, 2013
The U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee voted favorably by a majority,...
-
Dec 6, 2013New Retrospective Data Presented at NANS 2013 Show Highly Significant Reduction in Pain and High Trial Therapy Success Rate of Precision Spectra in the Treatment of Chronic Pain
New retrospective data highlighting the Boston Scientific Corporation (NYSE: BSX) Precision Spectra™ Spinal Cord Stimulator (SCS) System demonstrate...
-
Dec 6, 2013
Boston Scientific Corporation (NYSE: BSX) and The Medicines Company (NASDAQ: MDCO) announce a co-promotion agreement for the...
-
Nov 25, 2013Advanced Stent Technology to Launch Immediately in the United States
Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug...
-
Nov 22, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 25th Annual Piper Jaffray Healthcare Conference on December 3 in New...
-
Nov 21, 2013
Boston Scientific Corporation (NYSE: BSX) announces the appointment of Susan (Susie) Vissers Lisa as vice president, Investor Relations, effective...
-
Nov 19, 2013Boston Scientific Receives FDA Clearance And CE Mark Approval For Direxion™ Torqueable MicrocatheterProprietary Shaft Design Enables Better Control In Hard-To-Navigate Vessels
Further bolstering its market-leading portfolio of peripheral embolization technologies, Boston Scientific Corporation (NYSE: BSX) has received U.S....
-
Nov 19, 2013First System To Selectively Stimulate Targeted Areas Of The Brain To Manage Symptoms of Debilitating Disease
The Boston Scientific Corporation (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System has received CE Mark approval for the treatment...
-
Nov 15, 2013Patients In Germany Receive New Transcatheter Aortic Valve Implantation Devices Specially Designed For Total Control And Accurate Deployment
Marking a major step forward in the evolution of Transcatheter Aortic Valve Implantation (TAVI) technology, the first two commercial implants of the...
-
Nov 6, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2013 Credit Suisse Healthcare Conference on November 12 in Scottsdale,...
-
Nov 1, 2013
Boston Scientific Corporation (NYSE:BSX) today closed on its previously announced agreement to acquire Bard EP, the electrophysiology (EP) business of...
-
Oct 31, 2013New Data Announced At TCT 2013 Demonstrate Successful Deployment In All 120 Patients With No Severe Paravalvular Regurgitation At 30 Days
The Boston Scientific Corporation (NYSE: BSX) Lotus™ Valve System met a key performance measure in the treatment of symptomatic patients with...
-
Oct 31, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2013 Credit Suisse Healthcare Conference on November 12 in Scottsdale,...
-
Oct 28, 2013REDUCE-HTN Data Presented Today at TCT Demonstrate Excellent Safety Profile
Patients treated with the Boston Scientific (NYSE: BSX) Vessix™ Renal Denervation System experienced a significant and sustained reduction in blood...
-
Oct 28, 2013
Boston Scientific Corporation (NYSE: BSX) will highlight the strength of its advanced portfolio and plans for delivering additional meaningful...
-
Oct 28, 2013Transcatheter Aortic Valve Replacement (TAVR) Device Offers Precise Positioning and Placement, Offering Physicians Unprecedented Control
Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Lotus™ Valve System, the company's advanced transcatheter aortic valve...
-
Oct 24, 2013Jeffrey Capello to Transition Out of CFO Role at Year-End
Boston Scientific Corporation (NYSE: BSX) has initiated a transition plan for its new chief financial officer. Noting a desire to pursue opportunities...
-
Oct 24, 2013
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.735 billion and adjusted earnings per share of $0.17 for the third quarter ended...
Oct 23, 2013Revolutionary procedure clinically proven to provide long term reduction of asthma exacerbationsBoston Scientific Corporation (NYSE: BSX) has received China Food and Drug Administration approval for the Alair® Bronchial Thermoplasty System, an...
-
Oct 23, 2013Award Recognizes Innovative S-ICD® System, the World's First and Only Subcutaneous Implantable Defibrillator
The Boston Scientific Corporation (NYSE: BSX) S-ICD® System has received the Prix Galien USA 2013 Award for Best Medical Technology. The S-ICD...
-
Oct 10, 2013
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the third quarter ended September 30, 2013 on
-
Oct 9, 2013MAJESTIC Trial To Study Self-Expanding DES System Designed To Treat Superficial Femoral Artery (SFA) Lesions
Launching a key clinical trial expected to serve as the foundation for global regulatory approvals, a physician in Auckland, New Zealand has performed...
-
Oct 8, 2013University of Pittsburgh independent study of contemporary heart failure devices highlights industry-leading Boston Scientific battery longevity
An independent and first-of-its-kind study from the University of Pittsburgh Medical Center, published online this week in EP EuroPace, shows there are...
-
Oct 8, 2013Re-ROUTE Trial Data Presented At VIVA 2013 Late-Breaking Session
The Boston Scientific (NYSE: BSX) OffRoad™ Re-Entry Catheter System demonstrated excellent performance in facilitating the treatment of complete...
-
Sep 17, 2013
ORBUSNEICH, BOSTON SCIENTIFIC SETTLE PATENT LITIGATION Fort Lauderdale, Fla. and Natick, Mass. (September 17, 2013) -- OrbusNeich Medical Inc. and Boston Scientific Corporation (NYSE: BSX) have...
-
Sep 17, 2013
Reinforcing its ongoing commitment to leadership in the global medical technology market, Boston Scientific Corporation (NYSE: BSX) today officially...
Sep 17, 2013REPRISE II Data Honored as Best Abstract 2013 at PCR London Valves CourseBOSTON SCIENTIFIC REPORTS favorable SIX-MONTH RESULTS from LOTUS™ valve system clinical trial REPRISE II Data Honored as Best Abstract 2013 at PCR London Valves Course Natick, Mass. (Sept. 17,...
Sep 12, 2013In a significant milestone toward obtaining additional key regulatory approvals for the SYNERGY™ Stent System, Boston Scientific Corporation (NYSE:...
Sep 4, 2013Unlike Medications Alone, Bronchial Thermoplasty Provides Benefits That Last for Years Rather Than HoursA breakthrough Boston Scientific technology for the treatment of severe asthma has been shown to be safe and effective over at least five years,...
Sep 4, 2013Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2013 Stifel Nicolaus Healthcare Conference on Sept. 11 in Boston. Jeff...
- Sep 3, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2013 Morgan Stanley Global Healthcare Conference on Sept. 9 in New York....
Aug 21, 2013Shanghai, China (August 21, 2013) - The first patient implants of the Boston Scientific Corporation (NYSE: BSX) COGNIS™ cardiac resynchronization therapy defibrillator (CRT-D) were successfully...
Aug 21, 2013Boston Scientific Corporation (NYSE: BSX) continues to expand its electrophysiology (EP) offerings with U.S. Food and Drug Administration (FDA)...
-
Aug 19, 2013Innovative Bare Metal Stent Designed to Treat Peripheral Artery Disease
Boston Scientific Corporation (NYSE: BSX) has completed enrollment in the SuperNOVA trial – a global, single arm, prospective, multicenter trial...
-
Aug 13, 2013
Boston Scientific Corporation (NYSE: BSX) completed a public offering of $1.05 billion aggregate principal amount of its senior notes under the...
-
Aug 8, 2013
Boston Scientific Corporation (NYSE: BSX) announces the pricing of a public offering of $1.05 billion aggregate principal amount of its senior notes...
-
Jul 25, 2013
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.809 billion and adjusted earnings per share of $0.18 for the second quarter ended June...
-
Jul 24, 2013
Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Rhythmia™ Mapping System, a...
-
Jul 24, 2013Next generation intravascular ultrasound catheter improves image quality and deliverability
The Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration clearance, CE Mark and Japan PMDA approval for its...
-
Jul 19, 2013First Patient Treated in OPTIMISE Clinical Trial Evaluating Safety, Efficacy of Occipital Nerve Stimulation Using Precision™ System
Boston Scientific Corporation (NYSE: BSX) has launched a clinical trial to determine whether occipital nerve stimulation (ONS) using the Precision™...
-
Jul 12, 2013Device Facilitates Delivery of Interventional Devices in Complex PCI Procedures
Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration 510(k) clearance and CE Mark approval for the Guidezilla™...
-
Jul 11, 2013
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the second quarter ended June 30, 2013 on...
-
Jun 28, 2013Transaction to Accelerate Boston Scientific Expansion in Growing Electrophysiology Market
In a move that would significantly boost its capabilities in the fast-growing market for advanced electrophysiology procedures, Boston Scientific...
-
Jun 26, 2013
Paris (June 26, 2013) – The first patient implant of the Boston Scientific Corporation (NYSE: BSX) VITALIOTM pacemaker was performed at ZGT Hengelo in Hengelo, the Netherlands. In addition...
-
Jun 25, 2013
Paris (June 25, 2013) – Boston Scientific Corporation (NYSE: BSX) is launching a new family of pacemakers in Europe. These pacemakers monitor respiration, adjust pacing accordingly, and...
-
Jun 24, 2013Outcomes Follow Recent NICE Guidance Supporting Safety and Effectiveness of Subcutaneous Implantable Defibrillators
Paris (June 24, 2013) – The Boston Scientific Corporation (NYSE:BSX) S-ICD® (subcutaneous implantable defibrillator) System showed a significant reduction in major lead-related...
-
Jun 18, 2013VANTAGE Study Interim Data Presented at International Congress of Parkinson's Disease and Movement Disorders in Sydney
Patients with Parkinson's disease using the Boston Scientific Corporation (NYSE: BSX) Vercise™ DBS (deep brain stimulation) System showed a...
-
Jun 17, 2013First Implant of Company's Vercise Deep Brain Stimulation Device Designed to Treat Parkinson's
Boston Scientific Corporation (NYSE: BSX) announces the first implantation of its Vercise™ DBS System as part of the INTREPID clinical trial. ...
-
Jun 3, 2013
Boston Scientific Corporation (NYSE: BSX) continues to demonstrate its commitment to women's health by providing a research and education grant of more...
-
May 27, 2013GUIDE DBS is the World's First Deep Brain Stimulation Visual Simulation System
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for use of the GUIDE™ DBS System, the world's first deep brain stimulation...
-
May 24, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 38th Annual Deutsche Bank 2013 Healthcare Conference on May 30 in Boston....
-
May 22, 2013Interim Data from REDUCE-HTN Clinical Program Presented Today at EuroPCR
Boston Scientific Corporation (NYSE: BSX) today reported interim data from the REDUCE-HTN clinical program, which demonstrated a significant and sustained...
-
May 22, 2013New Data Presented In Late-Breaking Clinical Trial Session At EuroPCR Demonstrated Successful Deployment Of The Lotus™ Valve In The First 60 Patients With Minimal Paravalvular Regurgitation At 30 Days
Boston Scientific Corporation (NYSE: BSX) reports positive results from a pre-specified analysis of the first 60 patients enrolled in the REPRISE II trial...
-
May 22, 2013
Boston Scientific Corporation (NYSE: BSX) reports positive results from two trials evaluating new, innovative drug-eluting stent (DES) technologies, which are...
-
May 21, 2013
Five-year data from the Asthma Intervention Research 2 (AIR2) clinical trial presented today demonstrated that the Boston Scientific Corporation (NYSE:...
-
May 17, 2013
Boston Scientific Corporation (NYSE:BSX) is scheduled to participate in Digestive Disease Week (DDW®) 2013, May 18-21 in Orlando, Fla. More than 24...
-
May 17, 2013
Boston Scientific Corporation (NYSE:BSX) is scheduled to participate at the annual EuroPCR Scientific Program May 21-24 in Paris. "We are pleased to...
-
May 15, 2013Study Evaluates Clinical Outcomes of Self-Expanding Metal Stents as a Bridge to Surgery
The first patient has been enrolled in a clinical investigation evaluating the use of the Boston Scientific Corporation (NYSE: BSX) WallFlex® Biliary...
-
May 10, 2013Industry-Leading Battery Life Reduces the Frequency of Replacement Surgery
New data from 100,438 patients with Boston Scientific Corporation (NYSE:BSX) implantable cardiac defibrillators (ICDs) and cardiac resynchronization...
-
May 10, 2013Company Offers Mapping System with IntellaMap Orion™ Mapping Catheter in Effort to Significantly Enhance Physician Treatment Options
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the Rhythmia™ Mapping System, a next-generation 3D mapping and navigation...
-
May 9, 2013
Boston Scientific Corporation (NYSE: BSX) reports that the four-year follow-up data from the PROTECT AF clinical trial demonstrated the WATCHMAN® Left...
-
May 8, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bank of America Merrill Lynch 2013 Healthcare Conference on May 15 in Las...
-
May 6, 2013
Boston Scientific Corporation (NYSE: BSX) completed a first-in-human clinical trial utilizing the IntellaTip MiFi™ XP Ablation Catheter for the...
-
May 3, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate at Heart Rhythm 2013, the Heart Rhythm Society's 34th Annual Scientific Sessions...
-
Apr 25, 2013
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.761 billion and adjusted earnings per share of $0.16 for the first quarter ended March...
-
Apr 24, 2013Earth Week Celebration Focuses on 3,900-Panel Project at the Company’s International Distribution Center in Quincy
Natick, Mass. (April 24, 2013)—Boston Scientific Corporation (NYSE:BSX) celebrates Earth Week by inaugurating a 3,900-panel rooftop solar installation atop the company’s international...
-
Apr 15, 2013Innovative Device Quickly Anchors Leads and Catheters
Natick, Mass. (April 15, 2013) – Boston Scientific Corporation (NYSE: BSX) has acquired the fiXate™ Tissue Band and is launching the product in the United States. The fiXate Tissue Band is...
-
Apr 15, 2013
The first patient in the United States has been implanted with the Boston Scientific Corporation (NYSE: BSX) next generation ImageReady™ MR...
-
Apr 12, 2013World's First and Only System with Illumina 3D™ Software and 32 Contacts is Designed to Provide Pain Relief to a Broad Spectrum of Chronic Pain Patients
Boston Scientific Corporation (NYSE: BSX) has received approval by the U.S. Food and Drug Administration and is beginning a limited launch of the...
-
Apr 10, 2013
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2013 on...
-
Mar 21, 2013Results Revealed at CIT 2013
Platinum china trial demonstrates positive outcomes for the BOSTON SCIENTIFIC PROMUS ELEMENT™ STENT Results Revealed at CIT 2013 Beijing (March 21, 2013) – Boston Scientific Corporation...
-
Mar 13, 2013Deadly but Preventable Cancer is a Focus During Colorectal Cancer Awareness Month
NATICK, Mass., March 13, 2013 -- Boston Scientific Corporation (NYSE: BSX) is supporting several public education initiatives throughout the month of March to highlight the prevalence and...
-
Mar 10, 2013Separate Study Demonstrates PROMUS Element Stent has Significantly Less Vessel Straightening than the Xience V® Stent
Boston Scientific Corporation (NYSE: BSX) reported clinical endpoint data from the PLATINUM workhorse clinical trial comparing the safety and...
-
Mar 9, 2013WATCHMAN® Device Continues to Demonstrate Positive Clinical Outcomes for Patients with Atrial Fibrillation
Boston Scientific Corporation (NYSE: BSX) announces the preliminary analysis of the PREVAIL clinical trial data is now available on TCTMD at...
-
Mar 9, 2013
Boston Scientific Corporation (NYSE: BSX) reports preliminary data in the PREVAIL clinical trial met two out of three co-primary endpoints. The...
-
Mar 6, 2013First Presentation of the Preliminary Results of All Three Co-Primary Endpoints to be Revealed During The American College of Cardiology 2013 Annual Scientific Sessions
The Boston Scientific Corporation (NYSE: BSX) PREVAIL clinical trial results will be presented in a Late-Breaking Clinical Trial presentation at the...
-
Mar 6, 2013New Tool Available to Assist in the Treatment of Peripheral Arterial Disease
Boston Scientific Corporation (NYSE: BSX) has begun the launch of its 0.035" and 0.018" Rubicon™ Support Catheter in the United States. The device...
-
Mar 4, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to present sponsored research at the 62nd Annual Scientific Session of the American College of...
-
Feb 21, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2013 RBC Capital Markets Healthcare Conference on February 26 in New...
-
Feb 20, 2013
(Feb. 20, 2013 US Time) Boston Scientific Corporation (NYSE: BSX) subsidiary Boston Scientific Japan K.K. has reached an agreement with Fukuda Denshi Co., Ltd. to market and sell the Boston...
-
Feb 20, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Citi 2013 Global Healthcare Conference on February 25 in New York....
-
Feb 12, 2013The Next Advance in Durable Polymer Stent Technology from Boston Scientific is Now Available in Europe and Other Select Geographies
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent...
-
Feb 6, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2013 Leerink Swann Global Healthcare Conference on February 13 in New York....
-
Jan 29, 2013Organizations Team up to Raise awareness and Make a Call to Action for European Governments to Develop Comprehensive Chronic Pain Treatment Programs
Paris (January 29, 2013) – Boston Scientific Corporation (NYSE:BSX) today released results of a survey of more than 1,000 chronic pain sufferers across Europe that suggest millions of...
-
Jan 29, 2013
Boston Scientific Corporation (NYSE: BSX) announces financial results for the fourth quarter and full year ended December 31, 2012, as well as sales...